seekingalpha.comNov 10$SENS

Senseonics stock upgraded at Raymond James on Q3 (SENS:NASDAQ)

Senseonics (SENS) rose 30% after reporting Q3 2026 earnings above estimates and raising its full-year outlook. Raymond James upgraded the stock. The company makes glucose monitoring equipment.

Original reporting

seekingalpha.com

Published Nov 10, 2026, 3:33 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 10, 2026, 3:37 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Senseonics stock upgraded at Raymond James on Q3 (SENS:NASDAQ) — source image — Source · seekingalpha.com

Decision brief

The 30-second read

$SENSBullishHigh

Why it matters

The earnings beat and upgrade provide a clear catalyst for immediate price appreciation.

Market read

Strong earnings and an upgrade drive a 30%+ price jump, creating a short‑term trading opportunity.

What to watch

Potential reimbursement or regulatory risks not discussed in the brief.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Senseonics is a medical‑device maker focused on implantable continuous glucose monitoring systems.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$SENSBullishHigh confidence

Context

Senseonics reported better-than-expected Q3 2026 results, raised its full-year outlook and received a Raymond James upgrade, sending the stock up more than 30%.

Expected impact

upward bias as investors price in the upgraded outlook

Evidence & confidence

The combination of a surprise earnings beat, raised guidance and an analyst upgrade typically triggers short‑term demand.

Market effects

Sector

Positive signal for the continuous glucose monitoring sector, may lift peers.

Regional

U.S. healthcare stocks could see modest upside.

Global

Limited to U.S. and sector-specific investors.

Counterpoint

What could challenge this read

If the upgrade is already priced in, the stock could face short‑term profit taking.

Key entities

Analyst Firm
Raymond James
Upgraded Senseonics stock following earnings beat.

Read at source ← All news

$SENSMedAI 8/10

Senseonics surges 18% in premarket on Q3 beat, raised revenue outlook (SENS:NASDAQ)

Senseonics Holdings (SENS) rose 18% in premarket trading after reporting Q3 results that exceeded expectations and raising its revenue outlook. The company focuses on long-term implantable continuous glucose monitoring.

seekingalpha.comNov 10

$SENSHigh

Senseonics Shares Rise 12% As Q3 Revenue Jumps 140%; FY26 Outlook Raised

Senseonics (SENS) reported a 140% increase in Q3 2026 revenue to $19.6M, driven by strong U.S. sales of its Eversense 365 CGM system. The company raised its FY26 revenue guidance to $68M-$70M and increased gross margin outlook to over 60%. Net loss widened to $32.7M. SENS stock rose 12% on the news.

rttnews.comNov 10

$SENSMed

What Senseonics Holdings, Inc. Common Stock (SENS) Said on Its Q3 Earnings Call

Senseonics (SENS) reported Q3 gross profit of $12.1M (62% margin), up from $3.5M (43%) YoY. Net loss widened to $32.7M. The company raised its full-year gross margin outlook to over 60% and expects Freedom's margin to exceed 70%. It began human testing for Freedom, targeting a 2028 launch. Senseonics adjusted its 2026 Europe revenue share estimate to 15% from 20%.

finance.yahoo.comNov 9

$SENSMed

Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results

Senseonics Holdings, Inc. (SENS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results ● Generated third quarter revenue of $19.6 million, an increase of approximately 140% year-over-year ● Raised full-year 2026 revenue guidance to $68 million to $70 million from $62 million to $66 million, re

SEC EDGAR 8-KNov 9

$SENSMedAI 8/10

Senseonics begins first human trial of Freedom CGM

Senseonics Holdings has started the first human trial for its Freedom CGM system, which transmits data directly to mobile devices without an external transmitter. The trial focuses on safety and functionality, with plans for a pivotal trial in 2027 and potential commercial release in 2028. The device builds on the Eversense 365 system, aiming to eliminate external components. Preclinical assessments were completed in Q2 2026.

medicaldevice-network.comOct 27

$SYKMed

Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTech

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

tradingview.comOct 7